导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.53% | 2833/4773 |
| 近一周 | -2.48% | 3928/5465 |
| 近一月 | -6.92% | 4374/5421 |
| 近一季 | -14.06% | 4228/5231 |
| 近半年 | -3.50% | 2501/4920 |
| 近一年 | 0.68% | 2650/4394 |
| 近两年 | 57.55% | 1301/2954 |
| 近三年 | 28.54% | 1139/2253 |
| 成立以来 | 95.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.94% 2570/4961 |
20.08% 1253/5312 |
- - |
- - |
| 2025 | 26.05% 1658/4813 |
-0.40% 2231/3635 |
-0.61% 2981/4076 |
29.95% 1201/4524 |
-2.01% 3061/4813 |
| 2024 | 11.92% 1289/3463 |
0.46% 974/2808 |
-4.23% 1483/3014 |
18.72% 948/3129 |
-2.02% 1927/3463 |
| 2023 | -15.75% 1658/2656 |
4.35% 973/2280 |
-6.04% 1581/2385 |
-7.79% 1625/2515 |
-6.81% 1932/2655 |
| 2022 | -26.12% 1371/2207 |
-18.25% 1314/1919 |
8.19% 380/2016 |
-16.18% 1414/2113 |
-0.36% 1598/2208 |
| 2021 | -1.27% 791/1822 |
-4.62% 878/1255 |
9.96% 507/1330 |
-8.12% 1104/1466 |
2.46% 590/1822 |
| 2020 | 44.42% 226/1250 |
-6.34% 481/1028 |
20.34% 275/1067 |
9.82% 615/1164 |
16.68% 154/1184 |
| 2019 | 55.58% 71/1092 |
39.13% 58/754 |
-3.30% 386/804 |
4.42% 202/850 |
10.74% 102/918 |
| 2018 | -31.61% 500/834 |
- - |
- - |
- - |
-13.33% 529/691 |
| 2017 | 28.51% 77/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.85% 330/605 |
- - |
- - |
- - |
- - |
| 2015 | 15.90% 137/575 |
- - |
- - |
- - |
- - |
| 2014 | 29.46% 168/237 |
- - |
- - |
- - |
- - |
| 2013 | -4.20% 85/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发深证100ETF联接A VS. 长安沪深300非周期A(740101) |